Skip to main content
. 2017 Aug 2;9(10):627–636. doi: 10.1177/1758834017724314

Figure 2.

Figure 2.

Safety profile of cabozantinib in the phase III METEOR trial compared with those of other drugs currently approved for renal cancer treatment. (a) Represents the main toxicities of all grades and (b) shows grade 3–4 toxicities.

HFS, hand-foot syndrome.